5 days ago

India’s Pharma Majors Pivot From US to Russia to Evade Tariff Risks

India’s pharmaceutical sector is aggressively accelerating plans to diversify its global export footprints beyond the United States, weaponizing alternative markets in response to escalating tariff pressures from Washington.

The strategic pivot, which targets expanded market shares in Russia, the Netherlands, and Brazil, comes as New Delhi attempts to insulate its prized generic drug industry from transactional US trade policies. The urgency of this diversification is underscored by a recent report from the International Monetary Fund (IMF), which notes that while India’s economy continues to show resilience, its manufacturing sector faces headwinds from higher US tariff structures. Further, aggressive fiscal pressures—including historical 50% tariffs imposed due to India’s procurement of Russian oil—have compounded trade vulnerabilities, forcing a structural recalibration among Indian multinational exporters

Moscow Synergy and Special Economic Zones

In a clear manifestation of this geographical pivot, prominent Indian pharmaceutical major Hetero Labs Limited has finalized an agreement with the city of Moscow to construct a new manufacturing plant. The deal, structured to deepen pharmaceutical integration within a specialized economic zone in the Russian capital, was formally inked on the sidelines of the St. Petersburg International Economic Forum (SPIEF 2026).

The memorandum of cooperation was signed by Anatoly Garbuzov, Minister of the Moscow Government and head of investment and industrial policy, and Murali Krishna Reddy, Director of Emerging Markets at Hetero Labs Limited.

“We believe that such a synergy between the city and foreign partners will help create the most promising, the most high-tech pharmaceutical drugs,” Garbuzov stated, noting that Moscow is actively looking for international expertise to support its sprawling domestic life sciences ecosystem, which comprises more than 300 operational industrial enterprises. “India is really the world leader in the production of various pharmaceuticals,” Garbuzov added.

Mitigating Tariff Risks with Sovereign Guarantees

The expansion will be executed via Makiz Pharma, a wholly owned Russian subsidiary of Hetero Labs. Sanjay Nayak, Chief Executive of Makiz Pharma, confirmed that the firm will establish a localized factory dedicated to producing advanced oncological therapeutics alongside other vital medical portfolios.

To de-risk the investment amid an increasingly complex geopolitical climate, the Russian government has provided the land for the facility within the highly incentivized Technopolis Moscow Special Economic Zone (SEZ). The capital city has further sweetened the deal by offering structural tax rebates and an assured buy-back guarantee for specific pharmaceutical products.

Hetero Labs, renowned globally for its production of highly complex active pharmaceutical ingredients (APIs) and finished dosage formulations, intends to use the plant to bolster regional supplies of essential therapies for HIV, hepatitis, cancer, and tuberculosis. Makiz Pharma already maintains an operational manufacturing footprint in Moscow, but this expansion scales up production capacity significantly.

A Structural Reshaping of Supply Chains

The Technopolis Moscow SEZ currently hosts 14 advanced biomedical firms, 10 of which have already achieved active production lines delivering drugs for autoimmune, oncological, cardiological, and rare metabolic conditions.

Analysts point out that India’s tactical shift into localized manufacturing hubs like Moscow and its recent trade deals with Europe and UK, mirrors broader shifts in global trade. Academic assessments of international trade emphasize that high tariffs structurally degrade localized productivity and alter cross-border sourcing patterns, regionalizing supply chains that were once hyper-globalized.

While India maintains massive volume market shares in the West—accounting for roughly 40% of the generic volume share in the US—restrictive regulatory and trade barriers are driving companies toward sovereign partnerships in the Global South and Europe.